We are live on ! Find out more
NVO

Novo Nordisk

553 hedge funds and large institutions have $8.16B invested in Novo Nordisk in 2018 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 156 increasing their positions, 206 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more call options, than puts

Call options by funds: $51.7M | Put options by funds: $16.3M

8% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 53

0% more funds holding

Funds holding: 552553 (+1)

0.12% more ownership

Funds ownership: 16.76%16.88% (+0.12%)

8% less capital invested

Capital invested by funds: $8.82B → $8.16B (-$665M)

24% less repeat investments, than reductions

Existing positions increased: 156 | Existing positions reduced: 206

26% less funds holding in top 10

Funds holding in top 10: 1914 (-5)

Holders
553
Holders Change
+1
Holders Change %
+0.18%
% of All Funds
12.67%
Holding in Top 10
14
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-26.32%
% of All Funds
0.32%
New
57
Increased
156
Reduced
206
Closed
53
Calls
$51.7M
Puts
$16.3M
Net Calls
+$35.4M
Net Calls Change
+$17.8M
Name Holding Trade Value Shares
Change
Change in
Stake
Capital Fund Management (CFM)
51
Capital Fund Management (CFM)
France
$18.7M -$1.84M -69,924 -8%
CBT
52
Capital Bank & Trust
California
$18.7M +$188K +7,168 +1%
ClearBridge Investments
53
ClearBridge Investments
New York
$18.4M -$5.54M -210,952 -22%
PFM
54
Parsec Financial Management
North Carolina
$18.3M +$212K +8,058 +1%
Stifel Financial
55
Stifel Financial
Missouri
$17.6M -$310K -11,804 -2%
HCM
56
Hutchinson Capital Management
California
$17.2M -$8.13M -309,774 -31%
O
57
OrbiMed
New York
$16.3M
GT
58
Glenmede Trust
Pennsylvania
$15.4M
CTA
59
Carillon Tower Advisers
Florida
$15.2M +$16.2M +617,018 New
Balyasny Asset Management
60
Balyasny Asset Management
Illinois
$14.6M +$15.6M +593,560 New
SCCM
61
Schafer Cullen Capital Management
New York
$14.5M -$917K -34,940 -6%
BTS
62
BB&T Securities
Virginia
$13.4M +$1.1M +42,032 +8%
DAC
63
Dividend Assets Capital
South Carolina
$12.6M -$13M -494,068 -49%
GCC
64
Guardian Capital (Canada)
Ontario, Canada
$12.6M +$1.66M +63,174 +14%
VanEck Associates
65
VanEck Associates
New York
$12.2M -$577K -21,970 -4%
US Bancorp
66
US Bancorp
Minnesota
$11.3M -$179K -6,830 -1%
Citadel Advisors
67
Citadel Advisors
Florida
$11.3M +$6.69M +254,820 +125%
CSIC
68
Clifford Swan Investment Counsel
California
$11.2M -$2.76M -104,956 -19%
Invesco
69
Invesco
Georgia
$11M -$9.36M -356,442 -44%
FCH
70
Freestone Capital Holdings
Washington
$11M +$512K +19,486 +5%
SCM
71
SKBA Capital Management
California
$10.9M -$2.69M -102,600 -19%
LHC
72
Levy Harkins & Co
New York
$10.8M -$826K -31,450 -7%
BC
73
Brinker Capital
Pennsylvania
$10.8M +$156K +5,952 +1%
NPA
74
Nichols & Pratt Advisers
Massachusetts
$10.6M
BFM
75
Boston Financial Management
Massachusetts
$10.6M -$258K -9,810 -2%

NVO Hedge Fund Activity: Q1 2018 in Review

553 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2018, worth a combined $8.16B — down 7.5% from $8.82B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new NVO positions and 53 closed out — a net gain of 4 holders — while 156 added to existing stakes and 206 trimmed.

The largest buyer was Eaton Vance Management, adding an estimated $79.2M. The largest seller was Folketrygdfondet, cutting an estimated $61.9M.

  • 553 institutional investors held Novo Nordisk (NVO) as of Q1 2018, up from 552 in Q4 2017.
  • Funds reported $8.16B of Novo Nordisk stock for Q1 2018, down 7.5% quarter-over-quarter.
  • 57 funds opened new Novo Nordisk positions in Q1 2018 and 53 closed out, a net change of +4 holders.
  • The largest Novo Nordisk buyer in Q1 2018 was Eaton Vance Management, an estimated $79.2M added.
  • The largest Novo Nordisk seller in Q1 2018 was Folketrygdfondet, an estimated $61.9M sold.

Based on aggregated 13F filings for Q1 2018.